{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T05:24:53Z","timestamp":1782969893357,"version":"3.54.5"},"reference-count":58,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2017,6,1]],"date-time":"2017-06-01T00:00:00Z","timestamp":1496275200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,6,1]],"date-time":"2017-06-01T00:00:00Z","timestamp":1496275200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"Advancing Translational Sciences of the National Institutes of Health"},{"name":"Parkland Hospital Obstetric Research Center"}],"content-domain":{"domain":["ajog.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Obstetrics and Gynecology"],"published-print":{"date-parts":[[2017,6]]},"DOI":"10.1016\/j.ajog.2017.02.025","type":"journal-article","created":{"date-parts":[[2017,2,21]],"date-time":"2017-02-21T01:45:49Z","timestamp":1487641549000},"page":"600.e1-600.e9","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":84,"title":["17-alpha Hydroxyprogesterone caproate did not reduce the rate of recurrent preterm birth in a prospective cohort study"],"prefix":"10.1016","volume":"216","author":[{"given":"David B.","family":"Nelson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9799-7905","authenticated-orcid":false,"given":"Donald D.","family":"McIntire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"McDonald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Gard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula","family":"Turrichi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth J.","family":"Leveno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ajog.2017.02.025_bib1","series-title":"Preterm birth: causes, consequences, and prevention","year":"2007"},{"key":"10.1016\/j.ajog.2017.02.025_bib2","doi-asserted-by":"crossref","first-page":"426.e1","DOI":"10.1016\/j.ajog.2014.01.046","article-title":"Correlation between initial neonatal and early childhood outcomes following preterm birth","volume":"210","author":"Manuck","year":"2014","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ajog.2017.02.025_bib3","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1056\/NEJMoa035140","article-title":"National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network. Prevention of recurrent preterm delivery by 17 alpha-hydroxyprogesterone caproate","volume":"348","author":"Meis","year":"2003","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ajog.2017.02.025_bib4","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1067\/mob.2003.41","article-title":"Prophylactic administration of progesterone by vaginal suppository to reduce the incidence of spontaneous preterm birth in women at increased risk: a randomized placebo-controlled double-blind study","volume":"188","author":"da Fonseca","year":"2003","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ajog.2017.02.025_bib5","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1002\/uog.5158","article-title":"Progesterone vaginal gel for the reduction of recurrent preterm birth: primary results from a randomized, double-blind, placebo-controlled trial","volume":"30","author":"O\u2019Brien","year":"2007","journal-title":"Ultrasound Gynecol"},{"key":"10.1016\/j.ajog.2017.02.025_bib6","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1056\/NEJMoa067815","article-title":"Progesterone and the risk of preterm birth among women with a short cervix. Fetal Medicine Foundation Second Trimester Screening Group","volume":"357","author":"Fonseca","year":"2007","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ajog.2017.02.025_bib7","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1002\/uog.9017","article-title":"Vaginal progesterone reduces the rate of preterm birth in women with a sonographic short cervix: a multicenter, randomized, double-blind, placebo-controlled trial. PREGNANT Trial","volume":"38","author":"Hassan","year":"2011","journal-title":"Ultrasound Obstet Gynecol"},{"key":"10.1016\/j.ajog.2017.02.025_bib8","doi-asserted-by":"crossref","first-page":"124.e1","DOI":"10.1016\/j.ajog.2011.12.003","article-title":"Vaginal progesterone in women with an asymptomatic sonographic short cervix in the midtrimester decreases preterm delivery and neonatal morbidity: a systematic review and metaanalysis of individual patient data","volume":"206","author":"Romero","year":"2012","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ajog.2017.02.025_bib9","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1002\/uog.15953","article-title":"Vaginal progesterone decreases preterm birth \u226434 weeks of gestation in women with a singleton pregnancy and a short cervix: an updated meta-analysis including data from the OPPTMUM study","volume":"48","author":"Romero","year":"2016","journal-title":"Ultrasound Obstet Gynecol"},{"key":"10.1016\/j.ajog.2017.02.025_bib10","unstructured":"FDA. FDA approves drug to reduce risk of preterm birth in at-risk pregnancy women. Available at: http:\/\/www.fda.gov\/NewsEvents\/Newsroom\/PressAnnouncements\/ucm242234.htm. Accessed Feb. 4,\u00a02011."},{"key":"10.1016\/j.ajog.2017.02.025_bib11","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1097\/AOG.0b013e3182723b1b","article-title":"Prediction and prevention of preterm birth. Practice bulletin no. 130","volume":"120","year":"2012","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.ajog.2017.02.025_bib12","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.ajog.2012.03.010","article-title":"Progesterone and preterm birth prevention: translating clinical trials data into clinical practice","volume":"206","year":"2012","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ajog.2017.02.025_bib13","doi-asserted-by":"crossref","first-page":"B11","DOI":"10.1016\/j.ajog.2017.01.022","article-title":"SMFM Publications Committee. SMFM statement: the choice of progestogen for the prevention of preterm birth in women with singleton pregnancy and prior preterm birth","volume":"216","year":"2017","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ajog.2017.02.025_bib14","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1515\/jpm-2012-0272","article-title":"A\u00a0blueprint for the prevention of preterm birth: vaginal progesterone in women with a short cervix","volume":"41","author":"Romero","year":"2013","journal-title":"J\u00a0Perinat Med"},{"key":"10.1016\/j.ajog.2017.02.025_bib15","unstructured":"Clinical Trials. Confirmatory study of 17P versus vehicle for the prevention of preterm birth in women with a previous singleton spontaneous preterm delivery (PROLONG). Available at: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01004029. Accessed January 6,\u00a02017."},{"key":"10.1016\/j.ajog.2017.02.025_bib16","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1038\/bjc.2013.725","article-title":"Randomized controlled trials and population-based observational research: partners in the evolution of medical evidence","volume":"110","author":"Booth","year":"2014","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ajog.2017.02.025_bib17","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1056\/NEJMsb1609216","article-title":"Real-world evidence\u2013what is it and what can it tell us?","volume":"375","author":"Sherman","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ajog.2017.02.025_bib18","doi-asserted-by":"crossref","first-page":"47.e1","DOI":"10.1016\/j.ajog.2013.09.039","article-title":"Quality assessment of compounded 17-hydroxyprogesterone caproate","volume":"210","author":"Chang","year":"2014","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ajog.2017.02.025_bib19","doi-asserted-by":"crossref","first-page":"576.e1","DOI":"10.1016\/j.ajog.2007.01.039","article-title":"Recurrence risk for preterm delivery","volume":"196","author":"McManemy","year":"2007","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ajog.2017.02.025_bib20","doi-asserted-by":"crossref","first-page":"128.e1","DOI":"10.1016\/j.ajog.2013.10.008","article-title":"Relationship between 17-alpha hydroxyprogesterone caproate concentration and spontaneous preterm birth","volume":"210","author":"Caritis","year":"2014","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ajog.2017.02.025_bib21","doi-asserted-by":"crossref","first-page":"376.e1","DOI":"10.1016\/j.ajog.2015.12.010","article-title":"Predictors of response to 17-alpha hydroxyprogesterone caproate for prevention of recurrent spontaneous preterm birth","volume":"214","author":"Manuck","year":"2016","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ajog.2017.02.025_bib22","first-page":"379","article-title":"Recurrence of preterm birth in singleton and twin pregnancies","volume":"98","author":"Bloom","year":"2001","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.ajog.2017.02.025_bib23","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1056\/NEJM197510022931401","article-title":"Efficacy of 17alpha-hydroxyprogesterone caproate in the prevention of premature labor","volume":"293","author":"Johnson","year":"1975","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ajog.2017.02.025_bib24","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/0002-9378(83)91051-7","article-title":"The effect of 17 alpha-hydroxyprogesterone caproate on pregnancy outcome in an active-duty military population","volume":"146","author":"Hauth","year":"1983","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ajog.2017.02.025_bib25","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1111\/j.1471-0528.1990.tb01740.x","article-title":"Progestogen administration in pregnancy may prevent preterm delivery","volume":"97","author":"Keirse","year":"1990","journal-title":"Br J Obstet Gynecol"},{"key":"10.1016\/j.ajog.2017.02.025_bib26","unstructured":"FDA. Gestiva slides revision. Meeting of the Advisory Committee for Reproductive Health Drugs. Aug. 29, 2006. NDA 21-945, 17\u03b1-hydroxyprogesterone caproate (Gestiva). Available at: http:\/\/www.fda.gov\/ohrms\/dockets\/ac\/06\/slides\/2006-4227S1-02-03-FDA_Wesley_files\/frame.htm. Accessed Jan. 7,\u00a02017."},{"key":"10.1016\/j.ajog.2017.02.025_bib27","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.ajog.2013.04.027","article-title":"Progesterone is not the same as 17\u03b1-hydroxyprogesterone caproate: implications for obstetrical practice","volume":"208","author":"Romero","year":"2013","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ajog.2017.02.025_bib28","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.ajog.2015.10.934","article-title":"Prevention of preterm birth with vaginal progesterone or 17-alpha-hydroxyprogesterone caproate: a critical examination of efficacy and safety","volume":"214","author":"O'Brien","year":"2016","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ajog.2017.02.025_bib29","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1111\/j.0730-7659.2004.00315.x","article-title":"Progesterone and preterm: seventy years of \u201cd\u00e9j\u00e0 vu\u201d or \u201cstill to be seen\u201d?","volume":"31","author":"Keirse","year":"2004","journal-title":"Birth"},{"key":"10.1016\/j.ajog.2017.02.025_bib30","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1056\/NEJM200309113491115","article-title":"Prevention of recurrent preterm delivery by 17 alpha-hydroxyprogesterone caproate","volume":"349","author":"Brancazio","year":"2003","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ajog.2017.02.025_bib31","doi-asserted-by":"crossref","first-page":"453.e1","DOI":"10.1016\/j.ajog.2010.03.023","article-title":"17 alpha-Hydroxyprogesterone caproate vehicle, castor oil, enhances the contractile effect of oxytocin in human myometrium in pregnancy","volume":"202","author":"O\u2019Sullivan","year":"2010","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ajog.2017.02.025_bib32","first-page":"4","article-title":"Gestational diabetes: detection, management, and implications","volume":"16","author":"Carr","year":"1998","journal-title":"Clin Diab"},{"key":"10.1016\/j.ajog.2017.02.025_bib33","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.2337\/dc07-0564","article-title":"Increased incidence of gestational diabetes in women receiving prophylactic 17\u03b1-hydroxyprogesterone caproate for prevention of recurrent preterm delivery","volume":"30","author":"Rebarber","year":"2007","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ajog.2017.02.025_bib34","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1073\/pnas.54.4.1069","article-title":"The effect of progesterone on the human uterus","volume":"54","author":"Csapo","year":"1965","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.ajog.2017.02.025_bib35","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/0002-9378(85)90525-3","article-title":"Gap junctions and myometrial steroid hormone receptors in pregnant and postpartum rats: a possible cellular basis for the progesterone withdrawal hypothesis","volume":"151","author":"Saito","year":"1985","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ajog.2017.02.025_bib36","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.jsgi.2003.12.004","article-title":"Myometrial progesterone responsiveness and the control of human parturition","volume":"11","author":"Mesiano","year":"2004","journal-title":"J\u00a0Soc Gynecol Investig"},{"key":"10.1016\/j.ajog.2017.02.025_bib37","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1056\/NEJMcibr1100071","article-title":"How does progesterone relax the uterus in pregnancy?","volume":"364","author":"Zakar","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ajog.2017.02.025_bib38","first-page":"237","article-title":"Use of progesterone and progestin analogs for inhibition of preterm birth and other uterine contractility disorders","volume":"4","author":"Garfield","year":"2012","journal-title":"Facts Views Vis Obgyn"},{"key":"10.1016\/j.ajog.2017.02.025_bib39","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1042\/bj3010183","article-title":"Suppression of interleukin 8 production by progesterone in rabbit uterine cervix","volume":"301","author":"Ito","year":"1994","journal-title":"Biochem J"},{"key":"10.1016\/j.ajog.2017.02.025_bib40","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1095\/biolreprod56.3.575","article-title":"Hormonal regulation of matrix metalloproteinase 9\/gelatinase B gene expression in rabbit uterine cervical fibroblasts","volume":"56","author":"Imada","year":"1997","journal-title":"Biol Reprod"},{"key":"10.1016\/j.ajog.2017.02.025_bib41","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1177\/1933719108325757","article-title":"Medroxyprogesterone acetate modulates remodeling, immune cell census, and nerve fibers in the cervix of a mouse model for inflammation-induced preterm birth","volume":"16","author":"Yellon","year":"2009","journal-title":"Reprod Sci"},{"key":"10.1016\/j.ajog.2017.02.025_bib42","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/j.lfs.2011.12.024","article-title":"Anti-inflammatory effect of proteoglycan and progesterone on human uterine cervical fibroblasts","volume":"90","author":"Fukuyama","year":"2012","journal-title":"Life Sci"},{"key":"10.1016\/j.ajog.2017.02.025_bib43","doi-asserted-by":"crossref","first-page":"846.e1","DOI":"10.1016\/j.ajog.2015.08.010","article-title":"Vaginal progesterone, but not 17\u03b1-hydroxyprogesterone caproate, has anti-inflammatory effects at the murine maternal-fetal interface","volume":"213","author":"Furcron","year":"2015","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ajog.2017.02.025_bib44","doi-asserted-by":"crossref","first-page":"223.e1","DOI":"10.1016\/j.ajog.2013.01.020","article-title":"Prevention of preterm birth by progestational agents: what are the molecular mechanisms?","volume":"208","author":"Nold","year":"2013","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ajog.2017.02.025_bib45","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1016\/j.ajog.2006.06.013","article-title":"The use of progestational agents for preterm birth: lessons from a mouse model","volume":"195","author":"Elovitz","year":"2006","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ajog.2017.02.025_bib46","doi-asserted-by":"crossref","first-page":"135.e1","DOI":"10.1016\/j.ajog.2011.03.048","article-title":"Progesterone receptor polymorphisms and clinical response to 17-alpha-hydroxyprogesterone caproate","volume":"205","author":"Manuck","year":"2011","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ajog.2017.02.025_bib47","doi-asserted-by":"crossref","first-page":"321.e1","DOI":"10.1016\/j.ajog.2014.01.013","article-title":"Pharacogenomics of 17-alpha hydroxyprogesterone caproate for recurrent preterm birth prevention","volume":"210","author":"Manuck","year":"2014","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ajog.2017.02.025_bib48","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1097\/AOG.0b013e31821c2d75","article-title":"Unjustified increase in cost of care resulting from US Food and Drug Administration approval of Makena (17\u03b1-hydroxyprogesterone caproate)","volume":"117","author":"Cohen","year":"2011","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.ajog.2017.02.025_bib49","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1097\/01.AOG.0000150560.24297.4f","article-title":"Estimated effect of 17 alpha-hydroxyprogesterone caproate on preterm birth in the United States","volume":"105","author":"Petrini","year":"2005","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.ajog.2017.02.025_bib50","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1161\/CIRCULATIONAHA.105.594945","article-title":"Design of randomized controlled trials","volume":"115","author":"Stanley","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.ajog.2017.02.025_bib51","unstructured":"Clinical Trials. FAQ: clinical trial phases. Available at: https:\/\/www.nlm.nih.gov\/services\/ctphases.html. Accessed January 8,\u00a02017."},{"key":"10.1016\/j.ajog.2017.02.025_bib52","first-page":"295","article-title":"The environment and disease: association or causation?","volume":"58","author":"Bradford Hill","year":"1965","journal-title":"Proc R Soc Med"},{"key":"10.1016\/j.ajog.2017.02.025_bib53","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1002\/sim.6825","article-title":"Exposure-wide epidemiology: revisiting Bradford Hill","volume":"35","author":"Ioannidis","year":"2016","journal-title":"Stat Med"},{"key":"10.1016\/j.ajog.2017.02.025_bib54","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1161\/CIRCULATIONAHA.107.703579","article-title":"Beyond the randomized clinical trial: the role of effectiveness studies in evaluating cardiovascular therapies","volume":"118","author":"Nallamothu","year":"2008","journal-title":"Circulation"},{"key":"10.1016\/j.ajog.2017.02.025_bib55","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/S0140-6736(14)61651-2","article-title":"A\u00a0population-based, multifaceted strategy to implement antenatal corticosteroid treatment versus standard care for the reduction of neonatal mortality due to preterm birth in low-income and middle-income countries: the ACT cluster-randomized trial","volume":"385","author":"Althabe","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.ajog.2017.02.025_bib56","first-page":"CD004454","article-title":"Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth","volume":"3","author":"Roberts","year":"2006","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.ajog.2017.02.025_bib57","unstructured":"SMFM Newsroom. Physicians weigh in on study in The Lancet on use of antenatal corticosteroids in prevention of pre-term birth. Available at: http:\/\/www.smfmnewsroom.org\/2014\/10\/physicians-weigh-in-on-study-in-the-lancet-on-use-of-antenatal-corticosteroids-in-prevention-of-pre-term-birth\/. Accessed January 8,\u00a02016."},{"key":"10.1016\/j.ajog.2017.02.025_bib58","doi-asserted-by":"crossref","unstructured":"Mcclure E, Goldenberg R, Swanson D, et\u00a0al. Routine antenatal ultrasound in low\/middle income countries: a cluster randomized trial. Abstract no. 3. Presented at: Society for Maternal-Fetal Medicine 37th Annual Meeting\u2013The Pregnancy Meeting; Jan. 23-28, 2017; Las Vegas, NV.","DOI":"10.1016\/j.ajog.2016.11.004"}],"container-title":["American Journal of Obstetrics and Gynecology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002937817302946?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002937817302946?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T11:13:23Z","timestamp":1757589203000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002937817302946"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6]]},"references-count":58,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2017,6]]}},"alternative-id":["S0002937817302946"],"URL":"https:\/\/doi.org\/10.1016\/j.ajog.2017.02.025","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.727331581.793534027","asserted-by":"object"}]},"ISSN":["0002-9378"],"issn-type":[{"value":"0002-9378","type":"print"}],"subject":[],"published":{"date-parts":[[2017,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"17-alpha Hydroxyprogesterone caproate did not reduce the rate of recurrent preterm birth in a prospective cohort study","name":"articletitle","label":"Article Title"},{"value":"American Journal of Obstetrics and Gynecology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajog.2017.02.025","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}